Home・Akcijų sąrašas・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

19.23 0.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.8

Max

19.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-24M -54M
Pardavimai	-2.5M 305M
Pelnas, tenkantis vienai akcijai	-0.15
Pelno marža	-17.851
Darbuotojai	3,100
EBITDA	-24M -32M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+175.38% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1B 3.7B
Ankstesnė atidarymo kaina	18.76
Ankstesnė uždarymo kaina	19.23

Naujienos nuotaikos

By Acuity

100%

320 / 340 reitingas Healthcare

Legend Biotech Corp ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 22:01; UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

2026-07-31 23:56; UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

2026-07-30 22:41; UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

2026-07-29 19:27; UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

2026-07-28 22:56; UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

2026-07-27 23:16; UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

2026-07-24 19:16; UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

2026-07-22 18:31; UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

2026-07-21 16:46; UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

2026-07-20 19:01; UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Akcijų palyginimas

Kainos pokytis

Legend Biotech Corp ADR Prognozė

Kainos tikslas

By TipRanks

175.38% į viršų

12 mėnesių prognozė

Vidutinis 52.35 USD 175.38%

Aukščiausias 80 USD

Žemiausias 28 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Legend Biotech Corp ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Legend Biotech Corp ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.